Bhargava Kandala

Statistics

Publications

Citations

149

H-Index

Active since

2018

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Bhargava Kandala is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, pharmacokinetics, and pharmacokinetic modeling.

ORCID

Publications per year

2018–2024

Publications

CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

Andrew J. Armstrong, Ravit Geva, Hyun Cheol Chung et al. · Investigational New Drugs · 2024 · 62 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical Evaluation of <scp>MK</scp>‐2640: An Insulin Analog With Glucose‐Responsive Properties

Alexander W. Krug, Sandra A. G. Visser, Kuenhi Tsai et al. · Clinical Pharmacology & Therapeutics · 2018 · 40 citations

Medicine, Pharmacokinetics, Pharmacology +16

Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?

Günther Hochhaus, Mong‐Jen Chen, Abhinav Kurumaddali et al. · The AAPS Journal · 2021 · 19 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

A Model‐Informed Drug Discovery and Development Strategy for the Novel Glucose‐Responsive Insulin MK‐2640 Enabled Rapid Decision Making

Sandra A. G. Visser, Bhargava Kandala, Craig Fancourt et al. · Clinical Pharmacology & Therapeutics · 2019 · 17 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

ModVizPop: A shiny interface for empowering teams to perform interactive pharmacokinetic/pharmacodynamic simulations

Pavan Vaddady, Bhargava Kandala · CPT Pharmacometrics & Systems Pharmacology · 2021 · 11 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

1–5 of 5